A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (NCT06131840)
An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (48 Sites)
Showing the first 25 of 48 sites.
- Mayo Clinic Hospital — Phoenix, Arizona
- Mayo Clinic — Scottsdale, Arizona
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- IP Address: City of Hope Investigational Drug Services(IDS) — Duarte, California
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
- University of Colorado Hospital — Aurora, Colorado
- Florida Cancer Specialists — Orlando, Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins — Baltimore, Maryland
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- START Midwest — Grand Rapids, Michigan
- Mayo Clinic Cancer Center — Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota
- MidAmerica Cancer Care — Kansas City, Missouri
- Sarah Cannon Research Institute - Pharmacy — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Dallas — Irving, Texas
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
- START Mountain Region — Salt Lake City, Utah
- South Texas Accelerated Research Therapeutics Mountain Region — West Valley City, Utah
- The Ottawa Hospital — Ottawa, Ontario
- University Health Network — Toronto, Ontario
- University Health Network, Princess Margaret Cancer Centre — Toronto, Ontario
- McGill University Health Centre — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Neoplasms
- S0820, Adenoma and Second Primary Prevention Trial — Birmingham, Alabama
- MyGI Diet for Colorectal Cancer Prevention — Ann Arbor, Michigan
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer — Gilbert, Arizona
- Combination Immunotherapy in Colorectal Cancer — Brooklyn, New York
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Encinitas, California
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... — Bethesda, Maryland
Explore by condition: All Colorectal Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.